FMR LLC has disclosed an increase in its beneficial ownership of Hemab Therapeutics Holdings, Inc., now holding 10.4% of the company's common stock. This update, filed on November 6, 2026, highlights FMR LLC's growing interest in Hemab, a company specializing in biological products.

Hemab Therapeutics, listed on the Nasdaq under the ticker COAG, operates within the Biological Products (No Diagnostic Substances) sector. The company is based in Cambridge, Massachusetts, and focuses on developing innovative therapies for patients with bleeding disorders.

The recent filing indicates that FMR LLC beneficially owns 4,871,850 shares of Hemab Therapeutics, with sole voting and dispositive power over these shares. Abigail P. Johnson, a director and the CEO of FMR LLC, is also noted as a beneficial owner of the same number of shares, reflecting the Johnson family's significant influence over the firm.

According to the filing, "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies." This suggests a coordinated approach to investment in Hemab, potentially impacting the company’s strategic direction.

This increase in ownership may affect various stakeholders, including existing shareholders, as it could signal FMR LLC's confidence in Hemab’s future prospects. The filing also notes that the Johnson family has a controlling interest in FMR LLC, which may have broader implications for the company.

Looking ahead, the filing does not specify what actions may follow this increase in ownership. However, it does indicate that FMR LLC and its affiliates are actively managing their investment positions in Hemab Therapeutics.